Stocktoria
GYRE THERAPEUTICS, INC. GYRE
Nasdaq · stock · Pharmaceutical Preparations · website · IPO 2006-04-12
GYRE THERAPEUTICS, INC. statistics & valuation
Market cap$701.3M
P / E71.0×
P / S6.0×
P / B11.2×
Net margin8.5%
Return on equity15.8%
FCF margin-0.2%
Return on capital5.9%
Graham number -92.2%$0.52
Market cap as of 2026-06-29. Multiples are price-derived and refreshed daily; everything else from the latest financial reports. The Graham number is Benjamin Graham's rough maximum fair value ($0.52); a green figure means the price is below it.
Profitability & efficiency
Margins and returns computed from annual filings. Falling shares outstanding = buybacks; rising = dilution. Net debt = debt − cash (negative = net cash).
Key ratios (by fiscal year)
| Ratio | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Gross margin | — | 96.3% | 95.9% | 95.3% | — | — | — | — | — | — |
| Operating margin | 9.9% | 15.3% | -59.3% | 9.0% | -1197.8% | -273.9% | — | -563700.0% | -2143.6% | — |
| Net margin | 8.5% | 16.9% | -75.3% | 4.2% | -1198.3% | -268.5% | — | -500916.7% | -2118.0% | — |
| FCF margin | -0.2% | -5.6% | 15.3% | 5.6% | -1152.8% | — | — | -482150.0% | -1961.0% | — |
| Return on assets | 4.5% | 14.3% | -73.3% | 5.1% | -158.0% | -59.3% | -56.0% | -24.1% | -54.6% | -44.5% |
| Return on equity | 15.8% | 28.3% | 540.1% | 6.0% | -147.9% | -73.9% | -80.7% | -25.1% | -70.1% | -105.4% |
| Current ratio | 6.28 | 3.32 | 2.85 | 4.06 | 3.63 | 5.03 | 3.32 | 25.83 | 4.48 | 1.71 |
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.